Literature DB >> 20388938

Valproic acid-associated vanishing bile duct syndrome.

Selim Gökçe1, Ozlem Durmaz, Coskun Celtik, Aysen Aydogan, Mine Güllüoglu, Semra Sökücü.   

Abstract

Hepatotoxicity as a result of valproic acid therapy is well documented. Elevation in aminotransferase activities is rarely associated with symptoms. It sometimes manifests as acute liver failure. Here, we report a 8-year-old girl who was referred for unresolving jaundice and itching for 3 months. Past history revealed afebrile convulsion 5 months previously and beginning of valproic acid treatment. Valproic acid was discontinued after the development of jaundice. Physical examination revealed ichterus, xanthomas on extensor surfaces of extremities, and hepatomegaly without any sign of chronic liver disease. Total and direct bilirubin levels were 20.2 and 12.9 mg/dL, respectively. Enzyme activities indicating cholestasis were increased together with blood cholesterol. Tests for infectious and autoimmune, metabolic, and genetic disorders were not informative. Liver biopsy revealed portal inflammation, severe bile duct loss, and cholestasis. The patient was considered to have valproic acid-associated vanishing bile duct syndrome, which has not been reported previously.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20388938     DOI: 10.1177/0883073809343474

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  7 in total

1.  Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.

Authors:  Matthew Mason; Oyedele Adeyi; Scott Fung; Barbara-Ann Millar
Journal:  BMJ Case Rep       Date:  2014-11-28

2.  Vanishing bile duct syndrome in human immunodeficiency virus infected adults: a report of two cases.

Authors:  Ana Paula Oppenheimer; Christopher Koh; Mary McLaughlin; John C Williamson; Thomas D Norton; Jennifer Laudadio; Theo Heller; David E Kleiner; Kevin P High; Caryn G Morse
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

3.  Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity.

Authors:  James B Adams; Tapan Audhya; Sharon McDonough-Means; Robert A Rubin; David Quig; Elizabeth Geis; Eva Gehn; Melissa Loresto; Jessica Mitchell; Sharon Atwood; Suzanne Barnhouse; Wondra Lee
Journal:  Nutr Metab (Lond)       Date:  2011-06-08       Impact factor: 4.169

4.  Protective effects of fennel oil extract against sodium valproate-induced hepatorenal damage in albino rats.

Authors:  Wael M Al-Amoudi
Journal:  Saudi J Biol Sci       Date:  2016-11-05       Impact factor: 4.219

5.  Vanishing bile duct syndrome with hyperlipidemia after ibuprofen therapy in an adult patient: a case report.

Authors:  Wen Xie; Qi Wang; Yuanjiao Gao; Calvin Q Pan
Journal:  BMC Gastroenterol       Date:  2018-09-29       Impact factor: 3.067

6.  Assessment of cholestasis in drug-induced liver injury by different methods.

Authors:  Mindan Xing; Lu Zhai; Jia Li; Qian Li; Min Gao; Jun Wen; Zengli Xu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

7.  Urosodeoxycholic Acid Therapy in a Child with Trimethoprim-Sulfamethoxazole-induced Vanishing Bile Duct Syndrome.

Authors:  Hyun Jeong Cho; Hye Jeong Jwa; Kyu Seon Kim; Dae Yong Gang; Jae Young Kim
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.